Phase 3 Leukaemia Trial, Recruiting NCT07342478 Sponsor: Newave Pharmaceutical Inc Condition: Leukaemia
Back to Leukaemia

Phase 3 Leukaemia Trial, Recruiting

NCT07342478
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have been diagnosed with a type of blood cancer called CLL or SLL, confirmed through laboratory testing of tissue samples using 2018 guidelines
  • People whose cancer has come back or stopped responding to treatment and now requires further treatment
  • People who have already received at least one previous treatment, including a specific type of medication known as a covalent BTK inhibitor
  • People whose cancer can be measured or detected through standard tests
  • People who are reasonably well and able to carry out daily activities, as assessed by a standard medical scale (a score of 0 to 2 on the ECOG scale — confirm with trial site)
  • People whose bone marrow, liver, and kidneys are functioning at an adequate level
  • People who have had their TP53 gene mutation status tested using a method called next-generation sequencing (NGS)
  • People who have had a specific chromosome change called 17p deletion tested using a method called FISH

Who may not be able to join:

  • People who have previously been treated with a non-covalent BTK inhibitor or a BTK degrader (a different category of BTK-targeting treatment)
  • People whose CLL or SLL has transformed into a more aggressive type of cancer known as Richter's transformation
  • People diagnosed with a related blood cancer called prolymphocytic leukemia
  • People with serious other health conditions or infections that are not well controlled
  • People whose CLL or SLL has spread to the central nervous system (the brain or spinal cord)
  • People who have or have had another type of cancer that currently requires active treatment (some exceptions may apply — confirm with trial site)
  • People who are pregnant or breastfeeding
  • People taking certain other medications or who have conditions that may interact in a way prohibited by the trial rules (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-206-335-3820

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Newave Pharmaceutical Inc
Registry
ClinicalTrials.gov
Start date
23 April 2026
Est. completion
30 October 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

PFS assessed by IRC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov